Nontoxic combretafuranone analogues with high in vitro antibacterial activity.
暂无分享,去创建一个
J. Vacek | P. Bartůněk | K. Konečná | J. Kuneš | M. Pour | P. Horky | D. Sedlák | M. Voráčová | M. Pour | Klára Konečná | David Sedlák | Petr Bartůněk | Jan Vacek
[1] E. Pelkey,et al. Synthesis and evaluation of the anti-proliferative activity of diaryl-3-pyrrolin-2-ones and fused analogs. , 2017, Bioorganic & medicinal chemistry letters.
[2] Wei Li,et al. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site. , 2016, Anti-cancer agents in medicinal chemistry.
[3] B. Monk,et al. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Apostolova,et al. Combretastatin A-4 analogues with benzoxazolone scaffold: Synthesis, structure and biological activity. , 2016, European journal of medicinal chemistry.
[5] G. Cholewiński,et al. Synthesis of Combretastatin A-4 Analogs and their Biological Activities. , 2016, Anti-cancer agents in medicinal chemistry.
[6] Gurneet Kaur,et al. Recent developments in tubulin polymerization inhibitors: An overview. , 2014, European journal of medicinal chemistry.
[7] Chunjian Liu,et al. Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4. , 2014, European journal of medicinal chemistry.
[8] M. J. Uddin,et al. Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. , 2014, ACS Medicinal Chemistry Letters.
[9] Jim Euchner. Design , 2014, Catalysis from A to Z.
[10] Madhusoodanan Mottamal,et al. Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents , 2014, Journal of medicinal chemistry.
[11] D. V. Tsyganov,et al. 3-(5-)-Amino-o-diarylisoxazoles: regioselective synthesis and antitubulin activity. , 2014, European journal of medicinal chemistry.
[12] K. Behnia,et al. Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties. , 2013, Journal of medicinal chemistry.
[13] Duane D. Miller,et al. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.
[14] D. Newman,et al. Anticancer Agents from Natural Products, Second Edition , 2011 .
[15] S. Remick,et al. Combretastatin A4 phosphate: a novel vascular disrupting agent. , 2010, Future oncology.
[16] Giovanni Sorba,et al. Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.
[17] D. Kingston,et al. Anticancer Agents from Natural Products , 2005 .
[18] N. Nam. Combretastatin A-4 analogues as antimitotic antitumor agents. , 2003, Current medicinal chemistry.
[19] E. Hamel,et al. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. , 2002, Journal of medicinal chemistry.
[20] N. Nam,et al. Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. , 2002, Bioorganic & medicinal chemistry letters.
[21] P. Koudelka,et al. 3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones: synthesis and biological activity of a novel group of potential antifungal drugs. , 2001, Journal of medicinal chemistry.
[22] M. Boyd,et al. Antineoplastic agents 442. Synthesis and biological activities of dioxostatin. , 2000, Anti-cancer drug design.
[23] G. Pettit,et al. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. , 1998, Anti-cancer drug design.
[24] M. Cushman,et al. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. , 1992, Journal of medicinal chemistry.
[25] P. Prasit,et al. Synthesis of Rofecoxib, (MK 0966, Vioxx® 4-(4′-Methylsulfonylphenyl)-3-Phenyl-2(5H)-Furanone), a Selective and Orally Active Inhibitor of Cyclooxygenase-2 , 2001 .